An understanding of the absolute benefits associated with estrogen suppression (aromatase inhibitors) or estrogen receptor blockade (tamoxifen) may also help clinicians to estimate the absolute risk of breast cancer recurrence or death if women use estrogen replacement therapy during or after completing adjuvant endocrine therapy. The gene discussed is CYP19A1; the disease is breast cancer.